Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAlmirall

Almirall

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:29:36.778282Z
Market Cap
1807.24M

Momentum Score

…

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
9.09
Low
13.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
10.44
Dividend Yield
1.84%
Revenue TTM
1114.53M
Revenue Per Share
5.21
Gross Profit TTM
854.40M
Debt / Equity
0.18
ROE
3.10%
Net Debt
-
ROCE
3.72%
Diluted EPS TTM
-0.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - 79.24M 128.28M 74.97M
Net income - - 74.28M 105.91M 77.67M
Selling general administrative - - 199.58M 198.15M 201.40M
Gross profit - - 634.93M 662.87M 594.34M
Ebit 67.61M 110.47M 109.14M 160.78M 109.19M
Operating income - - 92.30M 149.91M 86.99M
Other operating expenses 285.72M 226.77M 212.64M 226.42M 238.46M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - - 4.96M 22.37M -2.70M
Interest income - - 6.08M 12.95M 6.97M
Income tax expense 26.75M 31.77M 4.96M 22.37M -2.70M
Total revenue - - 807.43M 855.34M 756.93M
Cost of revenue - - 172.50M 192.47M 162.59M
Net income applicable to common shares 4.28M -40.86M 74.28M 105.91M 77.67M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 2291.11M 2439.79M 2389.51M
Intangible assets - - 1009.54M 1139.02M 1121.21M
Other current assets 14.78M 11.62M 10.06M 9.96M 4.17M
Total liab - - 988.15M 1159.60M 1197.76M
Total stockholder equity - - 1302.97M 1280.19M 1191.75M
Deferred long term liab 80.10M 72.14M 35.36M 30.66M 30.27M
Other current liab 40.45M 84.60M 25.55M 55.96M 19.29M
Common stock 21.78M 21.57M 21.37M 20.95M 20.86M
Retained earnings 8.56M -36.58M 78.47M 110.08M 81.83M
Other liab 169.67M 200.86M 270.12M 332.37M 398.15M
Good will - - 315.97M 315.97M 315.97M
Other assets 458.25M 481.82M 540.92M 417.05M 457.75M
Cash - - 159.64M 117.21M 85.19M
Total current liabilities 274.61M 280.99M 474.56M 316.53M 244.07M
Short term debt - - 2.61M 3.65M 3.26M
Short long term debt total - - 237.83M 484.79M 522.67M
Other stockholder equity 973.61M 1007.40M 931.50M 909.92M 859.10M
Property plant equipment 162.70M 123.81M 122.97M 121.80M 110.48M
Total current assets 552.72M 499.27M 489.75M 476.61M 414.37M
Net tangible assets 344.70M 249.20M 165.48M -144.14M -215.16M
Short term investments - - 6.03M 0.08M 1.08M
Net receivables 159.08M 161.72M 183.94M 243.00M 231.68M
Long term debt - - 224.34M 473.51M 522.67M
Inventory 130.09M 118.63M 130.15M 106.42M 92.33M
Accounts payable 184.29M 177.80M 162.14M 222.48M 191.02M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 47.03M 13.71M 51.93M
Change to liabilities - - 6.27M 11.00M -57.50M
Total cashflows from investing activities - - -68.54M -57.26M -23.52M
Net borrowings - - -17.20M -117.85M -25.17M
Total cash from financing activities - - -45.12M -134.88M -40.87M
Change to operating activities - - -13.82M -6.95M -7.07M
Net income 10.15M -38.47M 4.28M -40.86M 74.28M
Change in cash - - 41.44M 41.72M 48.37M
Total cash from operating activities - - 155.10M 233.85M 112.76M
Depreciation - - 113.76M 113.03M 117.12M
Other cashflows from investing activities - - 0.91M 0.18M 1.08M
Dividends paid - - 12.42M 11.75M 2.13M
Change to inventory - - -10.70M 13.34M -25.33M
Change to account receivables - - 2.88M -13.11M 105.98M
Sale purchase of stock - - - - -0.08M
Other cashflows from financing activities - - -15.55M -5.88M -13.48M
Change to netincome - - 45.55M 150.50M -100.68M
Capital expenditures 0.00M 0.00M 23.01M 18.81M 11.89M
Change in working capital - - - - -12.36M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Ronda General Mitre, 151, Barcelona, Spain, 08022

34 93 291 30 00

https://www.almirall.com

2108

Name Title Year Born
Mr. Carlos Gallardo Piqué Interim CEO & Pres of the Board 1972
Mr. Michael McClellan Exec. VP of Fin., CFO & Member of Management Board 1972
Mr. Joan Figueras Carreras Vice Sec., Member of Mgmt. Board, Non-Voting Director & Exec. Director of Corp. Governance NA
Mr. Eloi Crespo Cervera Sr. VP of Industrial Operations & Member of Management Board NA
Mr. Jordi Sabé Richer Sr. VP of Corp. Devel. & Member of Management Board NA
Mr. Esteve Conesa Panicot Sr. VP of HR & Member of Management Board NA
Dr. Volker Koscielny Chief Medical Officer & Member of Management Board NA
Mr. Pablo Alvarez Member of Management Board, Pres of Almirall US & GM of Almirall US NA
Dr. Karl Ziegelbauer Exec. VP of R&D, CSO and Member of Management Board NA
Mr. Paolo Cionini Chief Commercial Officer Europe & International and Member of Management Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…